Perampanel, a novel, noncompetitive, selective AMPA-receptor antagonist demonstrated evidence of efficacy in reducing motor symptoms in animal models of Parkinson's disease (PD). We assessed the safety and efficacy of perampanel for treatment of "wearing off" motor fluctuations in patients with PD. Patients (N = 263) were randomly assigned to once-daily add-on 0.5, 1, or 2 mg of perampanel or placebo. The primary objective was to determine whether there was a dose-response relationship for efficacy among the 3 perampanel doses and placebo. The primary efficacy endpoint for each treatment was measured as the least-squares (LS) mean change from baseline to week 12 in percent "off" time reduction during the waking day, as recorded by patient diaries. The primary efficacy analysis was a 1-sided Williams test for dose-response trend at the 0.025 level of significance. At week 12, dose-response trends, as determined by the Williams test, were not statistically significant for LS mean reduction in percent "off" time during the waking day (P = 0.061, with significance defined as P
DOI: 10.1002/mds.22974
PubMed: 20461807

---

Links toward previous steps (curation, corpus...)

• to stream PubMed, to step Corpus: 001831
• to stream PubMed, to step Curation: 001831
• to stream PubMed, to step Checkpoint: 001627

---

Links to Exploration step

pubmed:20461807

---

Le document en format XML

<record>

<TEI>

<teiHeader>

<fileDesc>

<titleStmt>

<title xml:lang="en">Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.</title>

<author>

<name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name>

<affiliation wicri:level="3">

<nlm:affiliation>German Competence Network on Parkinson's Disease, Department of Neurology, Philipps-University Marburg, Marburg, Germany.</nlm:affiliation>

<country xml:lang="fr">Allemagne</country>

<wicri:regionArea>German Competence Network on Parkinson's Disease, Department of Neurology, Philipps-University Marburg, Marburg</wicri:regionArea>

<placeName>

<region type="land" nuts="1">Hesse (Land)</region>

<region type="district" nuts="2">District de Giessen</region>

<settlement type="city">Marbourg</settlement>

</placeName>

</affiliation>

</author>

<author>

<name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name>

</author>

<author>

<name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>

</author>

<author>

<name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name>

</author>

<author>

<name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>

</author>

<author>

<name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>

</author>

<author>

<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name>

</author>

<author>

<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>

</author>

<author>

<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>

<affiliation>

<country>Autriche</country>

<placeName>

<settlement type="city">Innsbruck</settlement>

<region nuts="2" type="region">Tyrol (Land)</region>

</placeName>

<orgName type="university">Université de médecine d'Innsbruck</orgName>

</affiliation>

</author>

<author>

<name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>

</author>

<author>

<name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name>

</author>

<author>

<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>

</author>

<author>

<name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>

</author>

<author>

<name sortKey="Nappi, Giuseppe" sort="Nappi, Giuseppe" uniqKey="Nappi G" first="Giuseppe" last="Nappi">Giuseppe Nappi</name>

</author>

<author>

<name sortKey="Kostic, Vladimir" sort="Kostic, Vladimir" uniqKey="Kostic V" first="Vladimir" last="Kostic">Vladimir Kostic</name>

</author>

<author>

<name sortKey="Potic, Jagoda" sort="Potic, Jagoda" uniqKey="Potic J" first="Jagoda" last="Potic">Jagoda Potic</name>

</author>

<author>

<name sortKey="Ruzicka, Evzen" sort="Ruzicka, Evzen" uniqKey="Ruzicka E" first="Evzen" last="Ruzicka">Evzen Ruzicka</name>

</author>

<author>

<name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>

</author>

</titleStmt>

<publicationStmt>

<idno type="wicri:source">PubMed</idno>

<date when="2010">2010</date>

<idno type="doi">10.1002/mds.22974</idno>

<idno type="RBID">pubmed:20461807</idno>

<idno type="pmid">20461807</idno>

<idno type="wicri:Area/PubMed/Corpus">001831</idno>

<idno type="wicri:Area/PubMed/Curation">001831</idno>

<idno type="wicri:Area/PubMed/Checkpoint">001627</idno>

<idno type="wicri:Area/Ncbi/Merge">002B71</idno>

</publicationStmt>

<sourceDesc>

<biblStruct>

<analytic>

<title xml:lang="en">Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.</title>

<author>

<name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name>

<affiliation wicri:level="3">

<nlm:affiliation>German Competence Network on Parkinson's Disease, Department of Neurology, Philipps-University Marburg, Marburg, Germany.</nlm:affiliation>

<country xml:lang="fr">Allemagne</country>

<wicri:regionArea>German Competence Network on Parkinson's Disease, Department of Neurology, Philipps-University Marburg, Marburg</wicri:regionArea>

<placeName>

<region type="land" nuts="1">Hesse (Land)</region>

<region type="district" nuts="2">District de Giessen</region>

<settlement type="city">Marbourg</settlement>

</placeName>

</affiliation>

</author>

<author>

<name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name>

</author>

<author>

<name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>

</author>

<author>

<name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name>

</author>

<author>

<name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>

</author>

<author>

<name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>

</author>

<author>

<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name>

</author>

<author>

<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>

</author>

<author>

<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>

<affiliation>

<country>Autriche</country>

<placeName>

<settlement type="city">Innsbruck</settlement>

<region nuts="2" type="region">Tyrol (Land)</region>

</placeName>

<orgName type="university">Université de médecine d'Innsbruck</orgName>

</affiliation>

</author>

<author>

<name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>

</author>

<author>

<name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name>

</author>

<author>

<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>

</author>

<author>

<name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>

</author>

<author>

<name sortKey="Nappi, Giuseppe" sort="Nappi, Giuseppe" uniqKey="Nappi G" first="Giuseppe" last="Nappi">Giuseppe Nappi</name>

</author>

<author>

<name sortKey="Kostic, Vladimir" sort="Kostic, Vladimir" uniqKey="Kostic V" first="Vladimir" last="Kostic">Vladimir Kostic</name>

</author>

<author>

<name sortKey="Potic, Jagoda" sort="Potic, Jagoda" uniqKey="Potic J" first="Jagoda" last="Potic">Jagoda Potic</name>

</author>

<author>

<name sortKey="Ruzicka, Evzen" sort="Ruzicka, Evzen" uniqKey="Ruzicka E" first="Evzen" last="Ruzicka">Evzen Ruzicka</name>

</author>

<author>

<name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>

</author>

</analytic>

<series>

<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>

<idno type="eISSN">1531-8257</idno>

<imprint>

<date when="2010" type="published">2010</date>

</imprint>

</series>

</biblStruct>

</sourceDesc>

</fileDesc>

<profileDesc>

<textClass>

<keywords scheme="KwdEn" xml:lang="en">

<term>Adult</term>

<term>Aged</term>

<term>Antiparkinson Agents (adverse effects)</term>

<term>Antiparkinson Agents (therapeutic use)</term>

<term>Double-Blind Method</term>

<term>Female</term>

<term>Humans</term>

<term>Male</term>

<term>Middle Aged</term>

<term>Parkinson Disease (drug therapy)</term>

<term>Parkinson Disease (physiopathology)</term>

<term>Pyridones (therapeutic use)</term>

<term>Receptors, AMPA (antagonists & inhibitors)</term>

<term>Treatment Outcome</term>

</keywords>

<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">

<term>Antiparkinson Agents</term>

</keywords>

<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">

<term>Receptors, AMPA</term>

</keywords>

<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">

<term>Antiparkinson Agents</term>

<term>Pyridones</term>

</keywords>

<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">

<term>Parkinson Disease</term>

</keywords>

<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">

<term>Parkinson Disease</term>

</keywords>

<keywords scheme="MESH" xml:lang="en">

<term>Adult</term>

<term>Aged</term>

<term>Double-Blind Method</term>

<term>Female</term>

<term>Humans</term>

<term>Male</term>

<term>Middle Aged</term>

<term>Treatment Outcome</term>

</keywords>

</textClass>

</profileDesc>

</teiHeader>

<front>

<div type="abstract" xml:lang="en">Perampanel, a novel, noncompetitive, selective AMPA-receptor antagonist demonstrated evidence of efficacy in reducing motor symptoms in animal models of Parkinson's disease (PD). We assessed the safety and efficacy of perampanel for treatment of "wearing off" motor fluctuations in patients with PD. Patients (N = 263) were randomly assigned to once-daily add-on 0.5, 1, or 2 mg of perampanel or placebo. The primary objective was to determine whether there was a dose-response relationship for efficacy among the 3 perampanel doses and placebo. The primary efficacy endpoint for each treatment was measured as the least-squares (LS) mean change from baseline to week 12 in percent "off" time reduction during the waking day, as recorded by patient diaries. The primary efficacy analysis was a 1-sided Williams test for dose-response trend at the 0.025 level of significance. At week 12, dose-response trends, as determined by the Williams test, were not statistically significant for LS mean reduction in percent "off" time during the waking day (P = 0.061, with significance defined as P </div>

</front>

</TEI>

<pubmed>

<MedlineCitation Owner="NLM" Status="MEDLINE">

<PMID Version="1">20461807</PMID>

<DateCreated>

<Year>2010</Year>

<Month>05</Month>

<Day>12</Day>

</DateCreated>

<DateCompleted>

<Year>2010</Year>

<Month>08</Month>

<Day>17</Day>

</DateCompleted>

<DateRevised>

<Year>2012</Year>

<Month>11</Month>

<Day>15</Day>

</DateRevised>

<Article PubModel="Print">

<Journal>

<ISSN IssnType="Electronic">1531-8257</ISSN>

<JournalIssue CitedMedium="Internet">

<Volume>25</Volume>

<Issue>7</Issue>

<PubDate>

<Year>2010</Year>

<Month>May</Month>

<Day>15</Day>

</PubDate>

</JournalIssue>

<Title>Movement disorders : official journal of the Movement Disorder Society</Title>

<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>

</Journal>

<ArticleTitle>Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.</ArticleTitle>

<Pagination>

<MedlinePgn>896-905</MedlinePgn>

</Pagination>

<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22974</ELocationID>

<Abstract>

<AbstractText>Perampanel, a novel, noncompetitive, selective AMPA-receptor antagonist demonstrated evidence of efficacy in reducing motor symptoms in animal models of Parkinson's disease (PD). We assessed the safety and efficacy of perampanel for treatment of "wearing off" motor fluctuations in patients with PD. Patients (N = 263) were randomly assigned to once-daily add-on 0.5, 1, or 2 mg of perampanel or placebo. The primary objective was to determine whether there was a dose-response relationship for efficacy among the 3 perampanel doses and placebo. The primary efficacy endpoint for each treatment was measured as the least-squares (LS) mean change from baseline to week 12 in percent "off" time reduction during the waking day, as recorded by patient diaries. The primary efficacy analysis was a 1-sided Williams test for dose-response trend at the 0.025 level of significance. At week 12, dose-response trends, as determined by the Williams test, were not statistically significant for LS mean reduction in percent "off" time during the waking day (P = 0.061, with significance defined as P </AbstractText>

<CopyrightInformation>(c) 2010 Movement Disorder Society.</CopyrightInformation>

</Abstract>

<AuthorList CompleteYN="Y">

<Author ValidYN="Y">

<LastName>Eggert</LastName>

<ForeName>Karla</ForeName>

<Initials>K</Initials>

<AffiliationInfo>

<Affiliation>German Competence Network on Parkinson's Disease, Department of Neurology, Philipps-University Marburg, Marburg, Germany.</Affiliation>

</AffiliationInfo>

</Author>

<Author ValidYN="Y">

<LastName>Squillacote</LastName>

<ForeName>David</ForeName>

<Initials>D</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Barone</LastName>

<ForeName>Paolo</ForeName>

<Initials>P</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Dodel</LastName>

<ForeName>Richard</ForeName>

<Initials>R</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Katzenschlager</LastName>

<ForeName>Regina</ForeName>

<Initials>R</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Emre</LastName>

<ForeName>Murat</ForeName>

<Initials>M</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Lees</LastName>

<ForeName>Andrew J</ForeName>

<Initials>AJ</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Rascol</LastName>

<ForeName>Olivier</ForeName>

<Initials>O</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Poewe</LastName>

<ForeName>Werner</ForeName>

<Initials>W</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Tolosa</LastName>

<ForeName>Eduardo</ForeName>

<Initials>E</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Trenkwalder</LastName>

<ForeName>Claudia</ForeName>

<Initials>C</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Onofrj</LastName>

<ForeName>Marco</ForeName>

<Initials>M</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Stocchi</LastName>

<ForeName>Fabrizio</ForeName>

<Initials>F</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Nappi</LastName>

<ForeName>Giuseppe</ForeName>

<Initials>G</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Kostic</LastName>

<ForeName>Vladimir</ForeName>

<Initials>V</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Potic</LastName>

<ForeName>Jagoda</ForeName>

<Initials>J</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Ruzicka</LastName>

<ForeName>Evzen</ForeName>

<Initials>E</Initials>

</Author>

<Author ValidYN="Y">

<LastName>Oertel</LastName>

<ForeName>Wolfgang</ForeName>

<Initials>W</Initials>

</Author>

<Author ValidYN="Y">

<CollectiveName>German Competence Network on Parkinson's Disease</CollectiveName>

</Author>

</AuthorList>

<Language>eng</Language>

<PublicationTypeList>

<PublicationType UI="D016428">Journal Article</PublicationType>

<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>

<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>

</PublicationTypeList>

</Article>

<MedlineJournalInfo>

<Country>United States</Country>

<MedlineTA>Mov Disord</MedlineTA>

<NlmUniqueID>8610688</NlmUniqueID>

<ISSNLinking>0885-3185</ISSNLinking>

</MedlineJournalInfo>

<ChemicalList>

<Chemical>

<RegistryNumber>0</RegistryNumber>

<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>

</Chemical>

<Chemical>

<RegistryNumber>0</RegistryNumber>

<NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>

</Chemical>

<Chemical>

<RegistryNumber>0</RegistryNumber>

<NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance>

</Chemical>

<Chemical>

<RegistryNumber>H821664NPK</RegistryNumber>

<NameOfSubstance UI="C551441">perampanel</NameOfSubstance>

</Chemical>

</ChemicalList>

<CitationSubset>IM</CitationSubset>

<MeshHeadingList>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>

<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>

<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>

<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>

<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D011728">Pyridones</DescriptorName>

<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D018091">Receptors, AMPA</DescriptorName>

<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists & inhibitors</QualifierName>

</MeshHeading>

<MeshHeading>

<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>

</MeshHeading>

</MeshHeadingList>

</MedlineCitation>

<PubmedData>

<History>

<PubMedPubDate PubStatus="entrez">

<Year>2010</Year>

<Month>5</Month>

<Day>13</Day>

<Hour>6</Hour>

<Minute>0</Minute>

</PubMedPubDate>

<PubMedPubDate PubStatus="pubmed">

<Year>2010</Year>

<Month>5</Month>

<Day>13</Day>

<Hour>6</Hour>

<Minute>0</Minute>

</PubMedPubDate>

<PubMedPubDate PubStatus="medline">

<Year>2010</Year>

<Month>8</Month>

<Day>18</Day>

<Hour>6</Hour>

<Minute>0</Minute>

</PubMedPubDate>

</History>

<PublicationStatus>ppublish</PublicationStatus>

<ArticleIdList>

<ArticleId IdType="doi">10.1002/mds.22974</ArticleId>

<ArticleId IdType="pubmed">20461807</ArticleId>

</ArticleIdList>

</PubmedData>

</pubmed>

<affiliations>

<list>

<country>

<li>Allemagne</li>

<li>Autriche</li>

</country>

<region>

<li>District de Giessen</li>

<li>Hesse (Land)</li>

<li>Tyrol (Land)</li>

</region>

<settlement>

<li>Innsbruck</li>

<li>Marbourg</li>

</settlement>

<orgName>

<li>Université de médecine d'Innsbruck</li>

</orgName>

</list>

<tree>

<noCountry>

<name sortKey="Barone, Paolo" sort="Barone, Paolo" uniqKey="Barone P" first="Paolo" last="Barone">Paolo Barone</name>

<name sortKey="Dodel, Richard" sort="Dodel, Richard" uniqKey="Dodel R" first="Richard" last="Dodel">Richard Dodel</name>

<name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name>

<name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>

<name sortKey="Kostic, Vladimir" sort="Kostic, Vladimir" uniqKey="Kostic V" first="Vladimir" last="Kostic">Vladimir Kostic</name>

<name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J" last="Lees">Andrew J. Lees</name>

<name sortKey="Nappi, Giuseppe" sort="Nappi, Giuseppe" uniqKey="Nappi G" first="Giuseppe" last="Nappi">Giuseppe Nappi</name>

<name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name>

<name sortKey="Onofrj, Marco" sort="Onofrj, Marco" uniqKey="Onofrj M" first="Marco" last="Onofrj">Marco Onofrj</name>

<name sortKey="Potic, Jagoda" sort="Potic, Jagoda" uniqKey="Potic J" first="Jagoda" last="Potic">Jagoda Potic</name>

<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>

<name sortKey="Ruzicka, Evzen" sort="Ruzicka, Evzen" uniqKey="Ruzicka E" first="Evzen" last="Ruzicka">Evzen Ruzicka</name>

<name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name>

<name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>

<name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>

<name sortKey="Trenkwalder, Claudia" sort="Trenkwalder, Claudia" uniqKey="Trenkwalder C" first="Claudia" last="Trenkwalder">Claudia Trenkwalder</name>

</noCountry>

<country name="Allemagne">

<region name="Hesse (Land)">

<name sortKey="Eggert, Karla" sort="Eggert, Karla" uniqKey="Eggert K" first="Karla" last="Eggert">Karla Eggert</name>

</region>

</country>

<country name="Autriche">

<region name="Tyrol (Land)">

<name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>

</region>

</country>

</tree>

</affiliations>

</record>

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B71 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002B71 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:20461807
   |texte=   Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:20461807" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024